X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.prnewswire.com/news-releases/sumitomo-pharma-announces-availability-of-orgovyx-relugolix-in-canada-the-first-and-only-oral-androgen-deprivation-therapy-treatment-for-men-with-advanced-prostate-cancer-302086280.html
https://www.indianpharmapost.com/news/sumitomo-pharma-announces-authorization-in-canada-of-orgovyx-for-treatment-prostate-cancer-14828
https://www.prnewswire.com/news-releases/sumitomo-pharma-announces-authorization-in-canada-of-orgovyx-relugolix-for-the-treatment-of-men-with-advanced-prostate-cancer-301963903.html
https://www.ema.europa.eu/en/documents/overview/ryeqo-epar-medicine-overview_en.pdf
https://www.fiercepharma.com/pharma/myovant-pfizers-myfembree-wins-fda-nod-endometriosis
https://www.globenewswire.com/news-release/2022/08/06/2493463/0/en/Myovant-Sciences-and-Pfizer-Receive-U-S-FDA-Approval-of-MYFEMBREE-a-Once-Daily-Treatment-for-the-Management-of-Moderate-to-Severe-Pain-Associated-With-Endometriosis.html
https://www.fiercepharma.com/pharma/pfizer-myovants-myfembree-back-track-endometriosis-nod-aug-execs-say
https://www.ema.europa.eu/en/documents/overview/orgovyx-epar-medicine-overview_en.pdf
https://www.expresspharma.in/myovant-sciences-and-accord-healthcare-enter-into-exclusive-licence-agreement-to-commercialise-orgovyx-for-prostate-cancer-in-europe/
https://www.biospace.com/article/myovant-stumbles-on-fda-concerns-over-pfizer-partnered-endometriosis-drug/
https://www.globenewswire.com/news-release/2022/02/25/2392377/0/en/Myovant-Sciences-Receives-Positive-CHMP-Opinion-for-ORGOVYX-relugolix-for-the-Treatment-of-Advanced-Prostate-Cancer.html
https://www.pharmatimes.com/news/mhra_licenses_ryeqo_for_symptoms_of_uterine_fibroids_1382246
http://www.pharmafile.com/news/592902/mhra-licenses-uterine-fibroid-treatment-women-great-britain
https://www.globenewswire.com/news-release/2021/09/09/2294109/0/en/Myovant-Sciences-and-Pfizer-Announce-FDA-Acceptance-of-Supplemental-New-Drug-Application-for-MYFEMBREE-for-the-Management-of-Moderate-to-Severe-Pain-Associated-With-Endometriosis.html
https://www.ema.europa.eu/en/documents/overview/ryeqo-epar-medicine-overview_en.pdf
https://endpts.com/myovant-adds-relugolix-data-in-uterine-fibroids-ahead-of-june-pdufa-mubadala-teams-up-with-uk-for-1b-fund/
https://www.fiercepharma.com/marketing/myovant-new-ceo-details-prostate-cancer-drug-orgovyx-launch-and-pfizer-marketing
https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-presents-additional-data-relugolix-0/
https://endpts.com/myovant-shows-disappointing-prostate-cancer-data-on-the-way-to-the-fda-stock-sinks/
https://endpts.com/myovant-shows-disappointing-prostate-cancer-data-on-the-way-to-the-fda-stock-sinks/
https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-announces-fda-acceptance-new-drug-application/
https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-presents-additional-data-relugolix-combination
https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-announces-positive-results-second-phase-3-0/
https://www.globenewswire.com/news-release/2020/06/23/2051665/0/en/Sumitovant-Biopharma-Announces-Priority-Review-and-FDA-Acceptance-of-Myovant-Sciences-New-Drug-Application-for-Once-Daily-Oral-Relugolix-for-Advanced-Prostate-Cancer.html
https://www.globenewswire.com/news-release/2020/06/22/2051118/0/en/Resverlogix-Reaches-Agreement-With-FDA-for-Key-Aspects-of-Apabetalone-Registration-Enabling-Study.html
https://endpts.com/looking-at-a-groundbreaking-advance-myovant-gets-a-priority-review-at-fda-agenus-g1-forge-new-china-deals/
https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-submits-new-drug-application-nda-fda-once-0
https://www.fiercebiotech.com/biotech/asco-myovant-details-prostate-cancer-data-for-triple-threat-relugolix
https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-announces-additional-positive-efficacy-and/
https://www.globenewswire.com/news-release/2020/05/18/2035240/0/en/Myovant-Sciences-Provides-Recent-Corporate-Updates-and-Reports-Financial-Results-for-Fourth-Fiscal-Quarter-and-Full-Fiscal-Year-Ended-March-31-2020.html
https://www.prnewswire.com/news-releases/sumitovant-biopharma-announces-publication-of-myovant-abstracts-detailing-additional-efficacy-and-safety-findings-from-phase-3-liberty-studies-in-uterine-fibroids-in-obstetrics--gynecology-301049697.html
https://www.fool.com/investing/2020/04/26/myovant-squares-off-with-abbvie-on-endometriosis-t.aspx
https://www.globenewswire.com/news-release/2020/04/27/2022465/0/en/Myovant-Sciences-Announces-Publication-of-Abstracts-Detailing-Additional-Efficacy-and-Safety-Findings-from-Phase-3-LIBERTY-Studies-in-Uterine-Fibroids-in-Obstetrics-Gynecology.html
https://www.prnewswire.com/news-releases/sumitovant-biopharma-reports-key-clinical-and-regulatory-milestones-by-myovant-sciences-301046868.html
https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-submits-new-drug-application-nda-fda-once-daily/
https://endpts.com/myovant-grabs-40m-upfront-in-regional-deal-for-relugolix-akero-announces-nash-success-but-covid-19-delays/
https://www.biospace.com/article/following-phase-iii-data-myovant-lines-up-to-seek-fda-approval-for-uterine-fibroid-treatment/
https://www.fiercebiotech.com/biotech/myovant-hits-goal-uterine-fibroid-phase-3-teeing-up-abbvie-showdown
Market Place
Share 
